The Polyvalent Role of CD30 for Cancer Diagnosis and Treatment

• Published in: Cells (Basel, Switzerland) Vol. 12; no. 13; p. 1783
• Main Authors: Dumitru, Adrian Vasile, Țăpoi, Dana Antonia, Halcu, Georgian, Munteanu, Octavian, Dumitrascu, David-Ioan, Ceaușu, Mihail Constantin, Gheorghișan-Gălățeanu, Ancuța-Augustina
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.07.2023; MDPI
• Subjects: Analysis; Anaplastic large-cell lymphoma; Antigens; Apoptosis; Autoimmune diseases; Biomarkers, Tumor - metabolism; Cancer; cancer treatment; Care and treatment; CD30; CD30 antigen; Cell surface; Cells; Cytotoxicity; Diagnosis; Disease; embryonal carcinoma; Gene expression; Golgi apparatus; Hodgkin Disease - metabolism; Hodgkin lymphoma; Hodgkin's lymphoma; Humans; Ki-1 Antigen - metabolism; Kinases; Leukemia; Ligands; Lymphatic system; Lymphocytes; Lymphocytes T; Lymphoma; Lymphoma - metabolism; Lymphoma, Large-Cell, Anaplastic - diagnosis; Lymphoma, Large-Cell, Anaplastic - drug therapy; Medical research; Proteins; Reed-Sternberg cells; Reed-Sternberg Cells - metabolism; Reed-Sternberg Cells - pathology; Review; T-cell lymphoma; Thymus gland; tumor marker; Tumor markers; Tumor necrosis factor; Tumor necrosis factor-TNF; Tumors; Romania; CD30; cancer treatment; anaplastic large cell lymphoma; embryonal carcinoma; tumor marker; Hodgkin lymphoma
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells12131783

CD30, also known as TNFRSF8 (tumor necrosis factor receptor superfamily member 8), is a protein receptor that is heavily glycosylated inside the Golgi apparatus, as well as a tumor marker that is found on the surface of specific cells in the body, including certain immune cells and cancer ones. This review aims to shed light on the critical importance of CD30, from its emergence in the cell to its position in diagnosing various diseases, including Hodgkin lymphoma, where it is expressed on Hodgkin and Reed-Sternberg cells, as well as embryonal carcinoma, anaplastic large cell lymphoma (ALCL), and cutaneous T-cell lymphoma (CTCL). In addition to its role in positive diagnosis, targeting CD30 has been a promising approach treating CD30-positive lymphomas, and there is ongoing research into the potential use of CD30-targeted therapies for autoimmune disorders. We aim to elaborate on CD30's roles as a tumor marker, supporting thus the hypothesis that this receptor might be the aim of cytostatic treatment.